Drug Combination Details
| General Information of the Combination (ID: C77192) | |||||
|---|---|---|---|---|---|
| Name | Elemene NP Info | + | Cetuximab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GLS2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPX4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SLC40A1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SLC7A11 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| In-vivo Model | A volume of 100 ul HCT116-luc cells suspension (2.5*106 cells/ml) was injected subcutaneously into right dorsal flank of mice (5-week-old female BALB/c nude mice). | |||||
| Experimental
Result(s) |
Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. | |||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GLS2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPX4 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SLC40A1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SLC7A11 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| In-vivo Model | HCT116 cells (2.5*105) were injected subcutaneously into right dorsal flank of 5-week-old female BALB/c nude. | |||||
| Experimental
Result(s) |
Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. | |||||
